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Myelin of the adult central nervous system (CNS) is one of the major sources of 
inhibition to axon regeneration following injury.  The three known myelin-derived inhibitors 
(Nogo, MAG, and OMgp) bind with high affinity to the Nogo-66 receptor (NgR) on axons to 
limit neurite outgrowth.  Here, we show that RNA aptamers can be generated that bind to NgR, 
compete with these inhibitors for binding to NgR, and promote axon elongation of neurons in 
vitro in the presence of these inhibitors.  Aptamers have key advantages over protein antagonists, 
such as low cost and ease of production, high specificity and affinity for a wide range of targets, 
and simplicity with which they can be chemically modified to increase stability in vivo.  The 
ability of aptamers to stimulate neurite elongation opens the possibility of reversing the 





Patients with spinal cord injury suffer from permanent functional deficits and paralysis 
due to the limited capacity of axons to regenerate.  Unlike their counterparts in the peripheral 
nervous system (PNS), damaged axons in the central nervous system (CNS) do not regenerate 
spontaneously because of an inhibitory environment.  Studies have shown that CNS myelin is a 
major source of inhibition to axon regeneration (Fournier et al., 2001; Domeniconi et al., 2002; 
K. C. Wang et al., 2002).  Trauma to the CNS can result in major disruptions in white matter 
tracts, including breakdown of myelin sheaths.  Products of this myelin breakdown come in 
contact with the surfaces of severed axons and inhibit regeneration.  The three known major 
myelin-derived inhibitors are Nogo-A, myelin-associated glycoprotein (MAG), and 
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oligodendrocyte myelin glycoprotein (OMgp).  All three bind with high affinity to the Nogo-66 
receptor (NgR) on axonal surfaces (Fournier et al., 2001; Domeniconi et al., 2002; K. C. Wang et 
al., 2002).  Enzymatic cleavage of NgR confirms this effect, in that it increases axon 
regeneration (Fournier et al., 2001).  Because NgR is a GPI-linked receptor and lacks an 
intracellular signaling domain, it relies on the transmembrane co-receptor, p75, to transduce the 
inhibitory signal.  The final step in the signaling pathway is the activation of RhoA, a small 
GTPase that regulates actin polymerization and inhibits axonal elongation in its active form.  
Nogo-A, MAG, and OMgp activate RhoA through the NgR/p75 receptor complex, and this 
NgR/p75-complex/RhoA pathway is postulated to be responsible for the inhibitory signals that 
prevent axon regeneration (Yamashita and Tohyama, 2003).  
Recent pharmacological methods to overcome CNS myelin inhibition involved the use of 
an anti-Nogo antibody (Schnell and Schwab, 1990; Bregman et al., 1995), RhoA inhibitors 
(Dergham et al., 2002; Fournier et al., 2003), a NgR antagonist peptide (GrandPre et al., 2002), 
and soluble NgR (Li et al., 2004).    
There are potential problems with these inhibitors as therapeutic agents.   For example, 
the direct blockade of RhoA with an inhibitor may disrupt other, crucial Rho-related cellular 
activities.  In contrast, the anti-Nogo antibodies are only specific for Nogo and do not disrupt 
MAG or OMgp action.  Because of this, it may be useful to identify high affinity inhibitors that 
more generally interact with the surface of NgR. 
Aptamers are single-stranded oligonucleotides that fold into unique three-dimensional 
structures, allowing them to bind to protein targets with high affinity and specificity. They are 
considered as an alternative to therapeutic antibodies by offering the same advantages of 
antibodies but can be chemically synthesized in a cell-free system.   Furthermore, aptamers have 
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a number of advantages over peptide and protein antagonists, including their relatively low cost 
of production, ease of GMP manufacture, and the simplicity with which they can be modified for 
signaling, immobilization, and stability (Jayasena, 1999; Rimmele, 2003; Nimjee et al., 2005; 
Lee et al., 2006).  Clinical studies have shown that aptamers have no or low immunogenicity, 
and are generally non-toxic (Eyetech Study Group, 2002; Eyetech Study Group, 2003), which is 
a great advantage in comparison to antibodies given the length of treatment period required for 
spinal cord injuries.  For example, Macugen, a pegylated 2-fluoro pyrimidine RNA aptamer and 
a potent inhibitor of the angiogenic regulatory protein, VEGF(165) (Cunningham et al., 2005; Ng 
and Adamis, 2005; Siddqui and Keating, 2005), was approved by the FDA for treatment of 
neovascular age-related macular degeneration in 2004. 
Here, we selected RNA aptamers that bind to NgR with high specificity and affinity.  
Most importantly, these aptamers were shown to compete with Nogo, MAG, and OMgp for 
binding to NgR.  Neurite outgrowth assays demonstrated that these aptamers can reverse the 
effect of these inhibitors in vitro.  
 
 
RESULTS AND DISCUSSION 
 
Selection of Anti-NgR aptamers 
A RNA pool containing 50 randomized positions (R50) flanked by two constant, primer-
binding regions was used as a starting point for selection.  The protein target was a fusion of the 
extracellular domain of NgR and the constant region of IgG.  In each round of selection, RNA-
binding species were separated from weak or non-binding species by passing the protein:nucleic 
acid complexes through a modified nitrocellulose filter.  Captured species were amplified via 
reverse transcription and PCR.  Negative selections were carried out to remove sequences that 
bound species (the filter, IgG, and BSA) other than the target.  Iterative rounds of selection and 
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amplification were performed until the target-binding sequences dominated the selected 
population. 
Binding progressively increased and saturated at round 10.  The selected population 
showed good specificity for NgR (36% RNA binding at 1 µM protein concentration), with little 
binding to BSA, IgG, or the filter (<1% RNA binding at 1 µM protein concentrations).  The 
population was cloned and sequenced, and a best-binding, dominant sequence (Clone 6) was 
identified.  To further improve affinity, additional variants were selected from a partially 
randomized pool based on Clone 6 that contained 70% wild-type and 30% non-wild type 
nucleotides.  This level of mutagenesis should allow the accumulation of not only additional 
functional residues, but also changes in or additions to base-paired structures.  In addition, a new 
selection was carried out with a slightly longer pool (N62) in order to identify aptamers that 
might cover larger swaths of the NgR surface and thereby prevent binding of multiple inhibitors.    
At the conclusion of both selections, 58 clones were sequenced:  29 from the Clone 6 doped re-
selection, and 29 from the N62 selection.  As expected, the best ligands for NgR were present 
multiple times in the selected populations (Table S1).  However, no strong consensus sequences 
or motifs emerged from either selection.  The diversity of aptamer sequences could mean that the 
selected aptamers interact in several different ways with NgR, a result that is consistent with the 
fact that very different myelin-derived inhibitors all bind to NgR.   
The best aptamers were selected after a competition assay that identified binders with the 
highest affinity for relatively non-overlapping sites (Figure S1).  The fact that the aptamers 
seemed to bind to non-overlapping sites on NgR is consistent with the selection of multiple, 
different sequences from both the original and doped sequence selections.   The selected 
aptamers bound NgR with Kd values from 21 to 61 nM (Table 1; Figure S2).  In comparison, 
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anti-Nogo antibodies bind to Nogo with Kd values of 8 µM and 1µM, for the wild-type and 
engineered II.1.8 mutant, respectively (Fiedler et al., 2002); while the NgR antagonist peptide 
NEP 1-40 shows half-maximum inhibition at 50nM (GrandPre et al., 2002).     
 
Aptamers generally block inhibitor binding to NgR 
The predicted protein structure of NgR includes a signal sequence, eight central leucine-
rich repeats (LRRs) flanked by a cysteine-rich C-terminal subdomian (LRRCT) and a smaller 
leucine-rich N-terminal subdomain (LRRNT) (Fournier et al., 2001; Barton, et al; 2003).  Studies 
suggest that all three inhibitors (MAG, Nogo, and OMgp) bind overlapping sites in the LRR 
repeat domains (Domeniconi et al., 2002; Wang et al., 2002).  For example, NEP1-40 peptide 
can significantly, but only partially block myelin inhibition (GrandPre et al., 2002).  This is 
because the peptide antagonist only blocks Nogo-66 mediated activity but not that of MAG 
(Fournier et al., 2002; Liu et al., 2002).   
To determine whether or not the aptamers could more generally interfere with inhibitor 
binding than did other reagents, we assayed five of the best binding sequences in competition 
with Nogo, MAG, and OMgp.  Remarkably, aptamers blocked more than one inhibitor 
simultaneously, and a modest diminution of aptamer binding (3-10 fold) was only seen at the 
highest total inhibitor concentration (3200nM) (Figure 1).   As might be expected, there was a 
direct correlation between the affinity of the aptamers for NgR and the ability of the aptamers to 
compete with inhibitors for binding.  The sequences with the lowest binding constants, Clone 40 
and Clone 83, also showed the lowest decrease in binding in the presence of the inhibitors.  
 
Aptamers localize to NgR-expressing neuronal and non-neuronal cell surfaces  
 7
 Microscopy confirmed the binding of fluorescently-labeled aptamers to dissociated dorsal 
root ganglia (DRG), which have previously been shown to express NgR on their surfaces 
(Ahmed et al., 2006).  After staining with a neuron-specific anti-beta III tubulin antibody, we 
found NgR expression in non-neuronal cell types in addition to DRG neurons (data not shown).  
To determine the nature of these non-neuronal, NgR-expressing cells, we stained the culture with 
an anti-S100 antibody, which identifies Schwann cells.   The co-localization of the anti-NgR 
aptamers with the anti-S100 antibody suggested that NgR is expressed on Schwann cells.  This 
discovery was further confirmed with an anti-NgR antibody, which again bound both neurons 
and Schwann cells (Figure 2).   There was little to no binding to a cell line (A431) that lacked 
NgR, although the 431 cells were readily stained with a positive control, an anti-EGFR aptamer 
(Figure S3). 
 The localization of anti-NgR aptamers and antibody to Schwann cell surface led us to 
speculate the role of NgR on these cells.  Schwann cells form the basis for nerve regeneration 
and repair in the PNS.  Upon losing contact with axons such as following injury, mature 
Schwann cells undergo developmental regression and proliferation to provide an environment 
inductive to axonal re-growth (Fawcett and Keynes; 1990).  However, Schwann cells were 
previously reported to express neither Nogo nor its receptor via in situ hybridization (Josephson, 
et al., 2002).  The difference between previous and our own findings might the age-dependent 
expression of NgR in Schwann cells.  The rat pups used in our experiments were newborns; 
whereas the mice pups used in the previous study were postnatal day 7.  NgR expression might 
be downregulated as the animals reach adulthood, as previously observed in the spinal cord for 
humans and mice (Josephsen, et al., 2002). 
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 Studies have shown that the lack of regeneration in the CNS is due to a hostile 
environment.  For example, injured CNS axons can extend over long distances in the presence of 
a peripheral nerve graft (David and Aguayo, 1981).  Given that PNS is significantly more 
permissive for growth relative to the CNS and that Schwann cells have a role in inducing axonal 
re-growth in the PNS, it is possible that these surface receptors act as competitive binders for 
myelin-derived inhibitors that might otherwise come in contact with growing axons.  Indeed, 
given the larger number of Schwann cells it is possible that they act as a 'buffer' for the varying 
amounts of myelin-derived inhibitors that may be released.  It is also interesting that these 
supporting cells express both NgR and myelin-proteins, such as MAG, but not Nogo and OMgp 
(Owens et al., 1990).  This suggests an interesting scenario in which early Schwann cells can 
express both inhibitors of neurite growth and proteins that will bind the inhibitors, allowing the 
concentrations of these inhibitors to be very finely tuned in order to fine-tune neurite outgrowth 
over time. 
 
Disinhibition of neurite outgrowth  
To the extent that aptamers can compete with the inhibitors Nogo, MAG, and OMgp for 
binding to NgR, they were likely to show one of two biological effects:  potentiation of neurite 
outgrowth (due to inhibition of the inhibitors) or inhibition of neurite outgrowth (due to 
mimicking of the inhibitors).  To choose between these hypotheses, dorsal root ganglia (DRG) 
were isolated from P1-P3 rats and dissociated into single cells.  The primary cultures included 
neurons and non-neuronal cells, such as Schwann cells.  Throughout the study, the mitotic 
inhibitor 5-fluoro-2’-deoxyuridine (5-FDU) was added to arrest proliferation of non-neuronal 
cells.   
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In accordance with previous studies (Chen et al., 2000; Grandpre et al., 2000; 
Mukhopadhyay et al., 1994; McKerracher et al., 1994; Wang et al., 2002), the three myelin-
derived inhibitors reduced axon elongation, as measured by the length of neurites formed in 
culture (p<0.0001).  Approximately 200-500 cells were measured for each condition in triplicate 
(Figure 3).  In contrast, the addition of aptamers increased growth significantly relative to the 
inhibitors-only control (p<0.001).  Recovery of growth ranged 80-91% relative to the no-
inhibitor control, almost a two-fold increase from full inhibition.  Clone 83, the aptamer with the 
lowest binding constant, resulted in the highest reversal of inhibition among the aptamers, 
although at the concentrations assayed all of the aptamers showed similar effects on neurite 
outgrowth.  In contrast, the negative control, random RNA sequences at the same concentration, 
did not affect axon elongation.  Because all RNA samples were prepared at the same time using 
the same reagents and methods, this shows that the aptamers promoted neurite outgrowth based 
on their particular sequences alone.  
Soluble NgR was used as a positive control and could also compete with inhibitors and 
increase neurite outgrowth (Li et al., 2004).  The soluble receptor at 1µM, a concentration more 
than 3-fold that of the inhibitors, was not as effective as the aptamers in reversing the inhibition.  
A further disadvantage of the soluble NgR(310)ecto is that it only sequesters inhibitors in a one-
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MATERIAL AND METHODS 
 
In Vitro Selection 
Aptamers against NgR were generated by in vitro selection, starting from synthetic DNA libraries.   For 
the R50 pool, an oligonucleotide containing a 50-nucleotide random region (N50) flanked by constant 
regions was synthesized:  5’- GATAATACGACTCACTATAGGGTTTACCTAGGTGTAGATGCT-
N50-AAGTGACGTCTGAACTGCTTCGAA-3’.  The underlined portion is the T7 RNA polymerase 
promoter region.  Similarly, the N62 pool consisted of a 62-nucleotide (N62) region flanked by a 
different pair of primers: 5’ - GATAATACGACTCACTATAGGCGCTCCGACCTTAGTCTCTG-N62-
GAACCGTGTAGCACAGCAGA - 3.’  Following in vitro transcription by T7 RNA polymerase 
(Epicenter Technologies, Madison, WI), the derived RNA library was purified on an 8% denaturing 
polyacrylamide gel, then eluted and precipitated.  In order to eliminate sequences from the population 
that bound to either the filter or the Fc region, an initial negative selection was carried out.  The RNA 
population (~200 pmol, 1014 sequences) was incubated with 200 pmol of recombinant human IgG Fc 
(R&D Systems, Minneapolis, MN) and 0.01% BSA for 30 mins at 37oC.  Bound species were separated 
from unbound on a modified cellulose filter (Millipore, Bedford, MA).  The sequences that passed 
through the filter were collected and then incubated with recombinant mouse Nogo receptor/Fc chimera 
(R&D Systems, Minneapolis, MN) in selection buffer (PBS, pH 7.4, 3mM MgCl2) for 30 mins.  
Separation through a modified cellulose filter again trapped proteins and bound RNAs.  After washing 
with 600µL Selection Buffer, RNA molecules were eluted from the filter in 200 nM NaCl, 50 mM Tris-
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HCl, pH 7.4, 10 mM DTT, and 6 mM MgCl2, and amplified by reverse transcription and the polymerase 
chain reaction (Invitrogen, Carlsbad, CA).  An aliquot of the amplified DNA template (~1µg or 20 pmol, 
roughly one-sixth of total amount of amplicon produced) was used in a transcription reaction to generate 
an RNA pool for the subsequent round of selection.  Iterative rounds of selection and amplification were 
performed until the target-binding sequences dominated the library population.  In later rounds, the 
protein: RNA ratio, the MgCl2 concentration, and the incubation time during the binding reaction were 
altered to increase stringency.  The protein:RNA ration was 1:1 for the first two rounds, and 1:2 for 
subsequent rounds (protein was kept constant at 200 pmol, and RNA was varied from 200 to 400 pmol).  
The MgCl2 concentration was 5mM for the first three rounds and 3mM for the subsequent rounds.  The 
incubation time was 30 mins for the first three rounds and 20 mins for later rounds.  Following 
sequencing, the MEME server [http://meme.sdsc.edu] was used to find potential sequence motifs.  
 Selections to optimize Clone 6, the dominant sequence from the initial selection (Table S1), 
were performed in a similar manner.  The sequence for the partially randomized pool based on Clone 6 
was 5’GGGTTTACCTAGGTGTAGATGCTCTCTCTATTTCATTCGTAGGCTATTGGTGCCGCA 
AATACTAGCTTTACGAAAGTGACGTCTGAACTGCTTCGAAAA - 3’, where the italicized residues 
indicate positions that were synthesized at 70% wild-type and 30% non-wild-type nucleotides.   
 
Binding Assays 
The selected population was characterized for binding to NgR using a filter-binding assay similar 
to that used for the selection.  The sequences were radioactively labeled in a transcription 
reaction using [α-32P]ATP (3000ci/mmol, 10mCi/ml, Perkin Elmer, Waltham, MA).  The labeled 
RNA was then incubated with 12.5, 18.75, 25, 37.5, 50, 75, 150, 300, and 500nM of the target 
protein (NgR/FC chimera).  To separate the RNA bound to protein from free RNA, the reaction 
was passed through a nitrocellulose (top) then a nylon (bottom) filter (Schleicher & Schuell, 
Keene, NH) on a vacuum manifold.  The nitrocellulose captured the RNA:protein complexes, 
while the nylon captured free RNA.  After washing with Selection Buffer (600 µL), the filters 
were dried and exposed to a PhosphorImager plate (GE Healthcare, Piscataway, NJ) to 
quantitiate the amount of retained radioactivity.  The fraction of a given RNA (population or 
aptamer) that bound the target proteins was calculated by comparing the counts retained on the 
filter with the total number of counts in the original RNA.  Binding to IgG and BSA were 
assayed similarly.  The maximum binding (Bmax) and dissociation constants (Kd) were fit using 












Competition Binding Assays 
Competition between aptamers and myelin-derived inhibitors was assayed by measuring the 
reduction in aptamer binding in the presence of the inhibitors.   The aptamers were again 
radioactively labeled during transcription as described above.  The NgR/Fc chimera (50 nM) was 
incubated with Nogo, MAG, and OMgp (R&D Systems, Minneapolis, MN, each at 200 nM or 
800 nM) for 5 mins.  Aptamers were then introduced and incubated with the mixture for 20 mins 
at 37oC.  The binding reaction was passed through filters on a vacuum manifold, and the filters 
were washed and quantified as described in the binding assays above.  The fraction of RNA 
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bound was measured.   Decreases in aptamer binding due the formation of inhibitor-NgR 
complexes were determined in comparison with an aptamer alone control. 
 
Neurite Outgrowth Assays 
Dorsal root ganglia (DRG) were removed from P1-P3 rats and trimmed to remove axons for 
accurate measurements of re-growth in RPMI (Sigma-Aldrich, St. Louis, MO).  DRGs were 
dissociated into single cells by incubation with 0.25% collagenase type I (Sigma-Aldrich) at 
37oC for 30 mins and 0.025% trypsin (Sigma-Aldrich, St. Louis, MO) for 37 oC for 10 mins.  
Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich) with 10% fetal bovine serum (Hyclone, 
Logan, UT) and 1% penicillin-streptomycin (Sigma-Aldrich) was added to dissociated cells, and 
the cells were plated in 24-well plates coated with 50 µg/ml poly-L-lysine (Sigma-Aldrich, St. 
Louis, MO) and 10 µg/ml laminin (Trevigen, Gaithersburg, MD) at a density of 50,000 cells/well.  
At the time of plating, 30 nM of 5-fluoro-2’-deoxyuridine (Sigma-Aldrich) was added to arrest 
proliferation of non-neuronal cell types.  The three myelin-derived inhibitors (each at a final 
concentration 100 nM), RNAse inhibitors at 1.6 Units/µl (Ambion, Austin, TX), and a given 
RNA (final concentration 10 µM) were added an hour after plating (to minimize interference 
with cell adherence).  After 24 hours of incubation, the cells were fixed in 4% paraformaldehyde, 
immunostained with a neuron-specific anti-β-tubulin III antibody (Abcam, Cambridge, MA) and 
an Alexa Fluor 488-labeled goat anti-rabbit IgG (Invitrogen, Carlsbad, CA) as the secondary 
antibody.  To assay the impact of compounds on neurite outgrowth the lengths of individual 
immunostained neurites were measured.  The cell density and growth time were optimized to 
ensure that neurons grew in relative isolation from each other and that neurites from nearby cells 
did not fasciculate.  An inverted fluorescence microscope (IX-70, Olympus) was used to 
visualize the cells, and images from the microscope were acquired using a color CCD video 
camera (Optronics Magna-Fire, model S60800).  Quantification of neurite outgrowth was 
performed over a sample of 200-500 neurons per condition using Leica QWIN Image Analysis 
software (Leica Microsystems, Bannockburn, IL).   Gray image processing was first used to 
identify all anti-β-tubulin III-stained neurons.  Cell bodies were subsequently removed using 
BINARY EDIT functions.  The curve lengths (defined as the length of the longest side of a 
rectangle having the same area and perimeter as the measured feature) of the remaining neurites 
on 200-500 neurons were measured and averaged.  The significance of the collected data was 
assessed using a pairwise t-test with Bonferroni correction (Table S2). 
 
Aptamer Localization 
In order to better label the aptamers, a 3’ extension was added by PCR.  The extensions were 5’ 
CTGGTCATGGCGGGCATTTAATTCTCGAAGCAGTTCAGACGTCACTT 3’ for the R50 
pool; and 5’ CTGGTCATGGCGGGCATTTAATTCTGCTGTGCTACACGGTTC 3’ for the 
N62 pool.  The italicized portions indicate regions of complementarity to a biotinylated 
oligonucleotide.  RNAs (1 µM) transcribed from the extended templates were purified and 
hybridized to the biotinylated oligonucleotide (5’ GAATTAAATGCCCGCCATGACCAG 3’) (1 
µM) by heating to 70oC for 3 mins and cooling to 25oC.  The RNA:DNA hybrid was further 
incubated with streptavidin:phycoerythrin (PE) (1uM) to generate fluorescent complexes.  
Dissociated DRGs were prepared as described above.  The entire aptamer:biotinylated 
oligonucleotide:streptavidin:PE complex was incubated with the dissociated DRG culture for 30 
mins in the presence of RNAse inhibitors at 1.6 units/µl (Ambion, Austin, TX).  The DRGs were 
then washed 3 times with selection buffer (PBS + 3 mM MgCl2), fixed in 4% paraformaldehyde, 
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and immunostained with a neuron-specific anti-β- ubulin III antibody (Abcam, Cambridge, MA) 
or an anti-S100 antibody (Abcam, Cambridge, MA) and an Alexa Fluor 488-labeled goat anti-
rabbit IgG (Invitrogen, Carlsbad, CA) as the secondary antibody.  Staining with a biotinylated 
anti-NgR antibody (R&D Systems, Minneapolis, MN) was performed similarly, except that the 
antibody was conjugated to streptavidin:PE.  Fluorescence images were collected using a Leica 
SP2 AOBS confocal microscope.  The brightness and contrast of images were enhanced in 
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FIGURES AND TABLES 
 
Table 1 
The sequences of the random regions of the aptamers tested in neurite outgrowth assays, 























Clone     Sequence     Bmax(%) Kd(nM) 
 40 ATAACACGACATCCATATGTCAGTGGTCTGTGTACTTACACGGTATTCGA   81+7 25+8 
79 ACTACACGAGGACCTACGACTACTACATTATGCCAACCGGTCTTGCTTCGACACAGATACCTC  85+8 60+16 
83 TTGCACAAGATACGGCTACCTGTATGCGGCAATCGGCATTAAATCTATCTAAGCCAGCAGTAAC   65+3 21+4 
110 ATAACACGACATCCATATGTCAGTGGTCTGTGTACGTACACGGTATTCGC   95+8 50+13 







SUPPLEMENTARY TABLES AND FIGURES 
 
Table S1.  Aptamer sequences.  The random regions of aptamers from the Clone 6 doped re-
selection (A) and the N62 selection (B) are shown.  Out of the 58 clones sequenced, there were 
23 distinct sequences.  Several 5-bp long motifs (colored) appeared in multiple aptamers.  (*) 
indicates a high-affinity sequence, most of which appeared multiple times in the cloned 
population, and which were competed with one another to identify aptamers that bound to 
distinct regions on NgR (Figure S1).  (**) indicates the highest affinity sequences that bound to 
relatively non-overlapping regions on NgR and that were further tested in neurite outgrowth 











Repeats Sequence Clone 
6(Initial Sequence) CTCTCTATTTCATTCGTAGGCTATTGGTGCCGCAAATACTAGCTTTACGA   0 
*27    CCTTATTCCCTAGTATACCAAGAGTGTTGTGTACTCCGCTTAGTATCCT  10 
*45    GAATCCCGCTCTGTTTAATCCCGGCATCTCCAGGAATTATACCTACAAC   4 
*39    TAAGCCCCAGTTTCATCGATAGTATTCGCATTGCGCTCAGCGAATGTA    4 
108    TTGTCACTTTCGTCCCTAGGTTATTGTTGCCCCAAATAACTTCTTTTTA   2 
105    CGCTGTTGTCCCTCCCTTGGAATCTACGGACAACCCACCCTACCTAGAGT   2 
**40    ATAACACGACATCCATATGTCAGTGGTCTGTGTACTTACACGGTATTCGA  1 
**110   ATAACACGACATCCATATGTCAGTGGTCTGTGTACGTACACGGTATTCGC    1 
26    CTCGTGATTGTATTCGTAAGTCATTAGTTACGCAATTAATGATTTACAG   1 
32    GATTTTATTTCAGTGTTAGGGTAGTCATTCCCTACATTCCACCTTTACTC  1 
29    TAATCCCCAGTTTCATCGATAGTATTCGCATTGCGCTCAGCGAATGTA  1 
30    TAACCCCCAGTTTCATCGATAGTATTCGCATTGCGCTCAGCGAATGTA   1 
33    TTCTCACTTTCGTCCCTAGGTTATAGGTCCCACACATTCCCGCCCTACTA    1 
A. R50 Doped Selection 
     Repeats Sequence Clone 
**79  ACTACACGAGGACCTACGACTACTACATTATGCCAACCGGTCTTGCTTCGACACAGATACCTC 13 
*81  ACAGCTAAACACATCTGTACGCGCGTTTACTAATACATGTTCTAAATAGACGTAGCGGTAAC  5 
*82  TATTAATTCACTGTTTGCAGTTGCCTCCTGTTCGTTTACTCTTTACCCTTAAACGACAGCCT  2 
**83  TTGCACAAGATACGGCTACCTGTATGCGGCAATCGGCATTAAATCTATCTAAGCCAGCAGTAAC 1 
**152  GGCGATAGTTTCTATAGCAAGGTACAGCATTCTCTCTCCCTATAGAACCAATCCAGTACTAGC  1 
78  ACTACGAGAGGACTTACGAATGAGACCATATGCCAACCGGTCTGGCTTCGACACAGATTCCTA  1 
80  GGAAACCCTAAGATCTGAAATTAATCCTCCCAGTACTACTCAGAAAAAAAACGCGACACAGCCC 1 
85  CAGACGTAGCGAAAGAGGGCCTGGGTAGGTACTGACACGGGGATTCGCCTTACGTGGGACGT  1 
88  AACACAGCTCCATGGACTTCTGAGTGGATGCGATCCATACTGGGATTAGCAGTGCCCTC   1 
92  TCAATACACGCTGAAATAGCACTGATTAATCCCGCACCATGGGGCATGTGCGATGCCCCTGC  1 
148  CCGAATGTCTTTGCTTCAACACTGTCAACTGTACGCGGCGTATATTCTACTCCAGCGGTAAC   1 
B. N62 Selection 
 23
Table S2.  P values obtained by pairwise t-test with Bonferroni correction.  Aptamers 
significantly increased growth compared to the inhibitor-only control.  Furthermore, the extent of 
outgrowth in aptamer-treated samples (Inh+C40, inh+C79, inh+C83, inh+C110) was statistically 
equivalent to that of the no-inhibitor control (Buffer). 
  




Inh+C40 Inh+C79 Inh+C83 Inh+C110 
Inhibitors 
(Inh) 
1.7e-15 -- -- -- -- -- -- 
Inh+ 
sol NgR 
0.0036 6.4e-05 -- -- -- -- -- 
Inh+C40 
 
0.1528   1.4e-08 1.0000   -- -- -- -- 
Inh+C79 
 
1.0000   9.3e-11 1.0000   1.0000   -- -- -- 
Inh+C83 
 
1.0000   1.8e-11 0.3207   1.0000   1.0000   -- -- 
Inh+C110 
 
1.0000   1.4e-09 1.0000   1.0000   1.0000   1.0000   -- 
Inh+C152 
 



















Figure S3.  Anti-NgR aptamers are specific for neuronal cell lines.  Biotinylated ptamers and 
antibodies were labeled using Alexa568 streptavidin.  The human epithelial carcinoma tissue 
culture cell line A431 expresses EGFR (epidermal growth factor receptor) but not NgR.  Thus an 
anti-NgR aptamer (Clone 40) and an anti-NgR antibody showed little binding to these cells (no 
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